This is research, not a buy or sell recommendation. Robo-advice in Taiwan requires an FSC licence; FEAF analyses, explains and monitors, and the investor makes the decision. Judgement thresholds are working rules pending review by the team's finance members.
Plain-language summary of valuation, growth, profitability, balance sheet, and recent MOPS filings.
Mixed picture: 1 strengths against 3 watch-outs. Weigh them against your own goals.
Points to watch for a moderate profile: see the items marked above.
In plain words
Company 4198 experienced revenue declines of -15.0% in 2025 and -14.5% year-on-year in Q2 2026, alongside weak profitability with a return on equity of -19.8% and a net margin of -23.5%. While liabilities represented a light debt load at 28.7% of total assets in Q2 2026, free cash flow was negative at -29 NT$ million in 2025. Furthermore, there are 2 verified alerts—including a cash capital increase by major subsidiary SRA on 2026-11-10—and 1 filing awaiting human review. Overall, this presents a mixed picture of 1 strength against 3 watch-outs. Ultimately, all investment decisions rest entirely with the investor.
Written by gemini-3.6-flash from the facts above; every number was checked against them.
Strengths
+Liabilities are only 28.7% of total assets (Q2 2026): a light debt load. source (Financials) →
Watch-outs
!Revenue fell -15.0% in 2025; latest quarter Q2 2026: -14.5% year on year. source (Financials) →
!Return on equity -19.8% with a -23.5% net margin: weak profitability. source (Key Stats) →
!Free cash flow was negative in 2025: -29 NT$ million, so spending exceeded operating cash. source (Financials) →
What to check before deciding
?Is the revenue decline temporary or structural?
?What would lift profitability, and how soon?
?What is the spending for, and when does it start paying back?
What the analysis found
!GrowthRevenue fell -15.0% in 2025; latest quarter Q2 2026: -14.5% year on year. source →
!ProfitabilityReturn on equity -19.8% with a -23.5% net margin: weak profitability. source →
+DebtLiabilities are only 28.7% of total assets (Q2 2026): a light debt load. source →
!Cash flowFree cash flow was negative in 2025: -29 NT$ million, so spending exceeded operating cash. source →
·Filings2 verified alert(s); latest on 2026-11-10: 代重要子公司瑞亞生醫股份有限公司(簡稱SRA)公告 董事會決議現金增資發行新股事宜 source →
·Filings1 filing(s) are held or rejected and wait for human review. source →